🔴 BLAZE-1 Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

Among high-risk ambulatory patients, bamlanivimab plus etesevimab led to a lower incidence of Covid-19–related hospitalization and death than did placebo and accelerated the decline in the SARS-CoV-2 viral load.

🔵 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

n this interim analysis, the REGN-COV2 antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline. Safety outcomes were similar in the combined REGN-COV2 dose groups and the placebo group

🔴 Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

Subcutaneous REGEN-COV prevented symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection in previously uninfected household contacts of infected persons. Among the participants who became infected, REGEN-COV reduced the duration of symptomatic disease and the duration of a high viral load.